FANGZHOU JIANKE (06086) surged over 8%. As of press time, the stock rose 8.23% to HK$4.34, with trading volume reaching HK$40.7762 million.

On the news front, Nature's news section recently published a report on China's medical large models, drawing widespread industry attention. The Chinese chronic disease management model mentioned in the Nature report represents one of the few global cases that deeply integrates AI with multiple chronic disease management and has achieved notable results. Currently, overseas markets still lack companies with substantial scale that deeply integrate AI with multiple chronic disease management. In contrast, innovative forces in the Chinese market are emerging in this sector and are poised to achieve breakthrough progress.

The report indicates that a new wave of AI technology represented by large models has emerged in recent years. FANGZHOU JIANKE has timely captured industry development trends and conducted corresponding explorations. In September this year, FANGZHOU JIANKE's Xingshi large model was officially launched, attracting attention not only from the medical field but also being keenly noticed by foreign scholars for its innovative model, marking its first appearance in Nature coverage.

As FANGZHOU JIANKE's "super digital brain," the Xingshi large model drives five major applications: AI Medication Assistant, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI Search. Each application targets specific scenarios for clinical and patient use, providing real-time precise assistance in areas such as medication guidance, patient education, diagnostic support, and medical literature queries. For example, the AI Academic Assistant product supports expert-level answer delivery through voice interaction with second-level voice broadcasting, aligning with the busy clinical scenarios of doctors and enhancing tool usage efficiency and user engagement.